Biological agents targeting on pro-inflammatory cytokines are developed, and 
provide a great impact on the medical management of rheumatoid arthritis (RA). 
Particularly, biologics against tumor necrosis factor(TNF) can not only induce 
great clinical improvement, but also halt structural damage on the joints. Now 
chimeric anti-TNFalpha monoclonal antibody, infliximab, full human anti-TNFalpha 
monoclonal antibody, adalimumab, and TNF receptor II (p75) -IgGFc fusion 
protein, etanercept, are widely used in the inflammatory disorders including RA. 
This review article shows the characteristics of these anti-TNF biologics on RA, 
and summarizes the efficacy as well as the safety of the agents.